Virchows Archiv B

, Volume 54, Issue 1, pp 241–245 | Cite as

In vitro and in vivo elimination of macrophage tumor cells using liposome-encapsulated dichloromethylene diphosphonate

  • Nico van Rooijen
  • Nel Kors
  • Hennie ter Hart
  • Eric Claassen


It is shown in the present study that RAW 264 tumor cells can be killed by liposomeentrapped dichloromethylene diphosphonate (DMDP), both in vitro and in vivo. DMDP is ingested by phagocytic cells when entrapped in liposomes. Once phagocytized the liposomal membranes are digested and the drug is released into the cell and is ready for action. In vitro, even low doses of liposome-entrapped DMDP caused an significant reduction in cell numbers. In vivo, liposome-encapsulated DMDP markedly reduced tumor formation in the liver, when given 1 day after injection of 1 × 106 RAW 264 tumor cells. Liposome-encapsulated DMDP, given 4 or more days after injection of the tumor cells had no significant effect. We concluded that tumor formation by RAW 264 cells is only susceptible to in vivo treatment with liposome-entrapped DMDP during a short period of time after injection of the cells. Obviously, phagocytosis of the tumor cells is reduced after this period making the cells less susceptible to treatment with the liposome-entrapped drug.

Key words

Liposomes Dichloromethylene di-phosphonate Macrophages RAW 264 cells Elimination Liver 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Claassen E, Van Rooijen N (1984) The effect of elimination of macrophages on the tissue distribution of liposomes containing 3H-methotrexate. Biochim Biophys Acta 802:428–434PubMedGoogle Scholar
  2. Claassen E, Van Rooijen N (1986) Preparation and characteristics of dichloromethylene-diphosphonate containing liposomes. J Microencapsul 3:109–114CrossRefGoogle Scholar
  3. Daemen T, Veninga A, Roerdink FH, Scherphof GC (1986) In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Res 46:4330–4335PubMedGoogle Scholar
  4. De Weger RA, Van Loveren H, Van Basten CDH, Oskam R, Van der Zeijst BAM, Den Otter W (1983) Functional activities of the NCTC 1469 macrophage-cell line: Comparison of the NCTC 1469 cell line with various other macrophagelike cell lines. J Reticuloendothel Soc 33:55–66PubMedGoogle Scholar
  5. Ducatman BS, Wick MR, Morgan TW (1984) Malignant histiocytosis: a clinical, histologic, and immunohistochemical study of 20 cases. Hum Pathol 15:368–377PubMedCrossRefGoogle Scholar
  6. Fidler LJ, Sone S, Fogler WE, Barnes ZL (1984) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78:1680–1684CrossRefGoogle Scholar
  7. Goldman R (1984) Induction of a high phagocytic capability in P388D1, a macrophage-like tumor cell line, by la, 25-dihydroxyvitamin D3. Cancer Res 44:11–19PubMedGoogle Scholar
  8. Isaacson P, Wright DH, Jones JB (1983) Malignant lymphoma of true histiocytic (monocyte/macrophage) origin. Cancer 51:80–91PubMedCrossRefGoogle Scholar
  9. Raschke WC, Baird S, Ralph P, Nakoinz I (1978) Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 15:261–267PubMedCrossRefGoogle Scholar
  10. Roholl PJM, Kleyne J, Pijpers HW, Van Unnik JAM (1985) Comparative immunohistochemical investigation of markers for malignant histiocytes. Hum Pathol 16:763–771PubMedCrossRefGoogle Scholar
  11. Thombre PS, Deodhar SD (1984) Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human C-reactive protein or crude lymphokines. Cancer Immunol Immunother 16:145–150PubMedCrossRefGoogle Scholar
  12. Turner RR, Wood GS, Beckstead JH, Colly TK, Horning SJ, Warnke RA (1984) Histiocytic malignancies. Morphologic, immunologie and enzymatic heterogeneity. Am J Surg Pathol 8:485–500PubMedCrossRefGoogle Scholar
  13. Van Loveren H, Hilgers J, De Bakker JM, De Weger RA, Brederoo P, Den Otter W (1983) Macrophage-like cell lines: Endogenous peroxidatic activity, cell surface antigens and colony-stimulating factor production. J Reticuloendothel Soc 33:221–229PubMedGoogle Scholar
  14. Van Rooijen N, Van Nieuwmegen R (1983) Use of liposomes as biodegradable and harmless adjuvants. Meth Enzymol 93:83–95PubMedCrossRefGoogle Scholar
  15. Van Rooijen N, Van Nieuwmegen R (1984) Elimination of phagocytic cells in the spleen after intravenous injection of liposome encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res 238:355PubMedCrossRefGoogle Scholar
  16. Van Rooijen N, Van Nieuwmegen R, Kamperdijk EWA (1985) Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylenediphosphonate. Ultrastructural aspects of elimination of marginal zone macrophages. Virchows Arch [Cell Pathol] 49:375–383CrossRefGoogle Scholar
  17. Van Rooijen N, Claassen E (1988) In vivo elimination of macrophages in spleen and liver, using liposome encapsulated drugs: Methods and applications. In: Gregoriadis G (ed) Liposomes as drug carriers. John Wiley, Chichester, UK, pp 131–143Google Scholar
  18. Xu ZL, Bucana CD, Fidler IJ (1984) In vitro activation of murine Kupffer cells by lymphokines or endotoxins to lyse syngeneic tumor cells. Am J Pathol 117:372–379PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • Nico van Rooijen
    • 1
  • Nel Kors
    • 1
  • Hennie ter Hart
    • 1
  • Eric Claassen
    • 1
  1. 1.Immunocytochemistry Unit, Department of Histology, Medical FacultyFree UniversityAmsterdamThe Netherlands

Personalised recommendations